The first edition of the European LeukemiaNet (ELN) recommendations for diagnosis and
management of acute myeloid leukemia (AML) in adults, published in 2010, has found …

Acute myeloid leukemia (AML) is the most common form of acute leukemia in adults and the
second most common form of acute leukemia in children. Despite this, very little …

The rapid development of next-generation sequencing (NGS) technology, including
advances in sequencing chemistry, sequencing technologies, bioinformatics, and data …

Biallelic mutations of the CEBPA gene (CEBPA bi) define a distinct entity associated with
favorable prognosis; however, the role of monoallelic mutations (CEBPA sm) is poorly …

The outlook for patients with acute myeloid leukaemia has improved in the past 30 years.
Unlike other cancers, much of this progress is attributable to refinement of supportive …

The choice of treatment approach and outcome in acute myeloid leukemia (AML) depends
on the age of the patient. In younger patients, arbitrarily defined as being younger than 60 …

Mutations of CCAAT/enhancer–binding protein alpha (CEBPA mu) are found in 10% to 15%
of de novo acute myeloid leukemia (AML) cases. Double-mutated CEBPA (CEBPA dm) is …

Abstract The revised 2022 European LeukemiaNet (ELN) AML risk stratification system
requires validation in large, homogeneously treated cohorts. We studied 1118 newly …

As more clinically-relevant genomic features of myeloid malignancies are revealed, it has
become clear that targeted clinical genetic testing is inadequate for risk stratification. Here …

Acute myeloid leukemia (AML) is characterized by accumulation of myeloid cells in the bone
marrow because of impaired differentiation and proliferation, resulting in hematopoietic …